Study guide

3.2 Community-Acquired Pneumonia, Hospital-Acquired Pneumonia & Tuberculosis

CAMC Regional Medical Registration Examination Part 1 MCQ

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview, Registration Framework & Test Strategy

1.1 Exam Format, Administration & Caribbean Medical Registration Pathways 1.2 Clinical Reasoning & Single-Best-Answer MCQ Test-Taking Strategy 1.3 Regional Epidemiology & Caribbean Healthcare Context

2 Chapter 2: Internal Medicine: Cardiovascular Disorders

2.1 Acute Coronary Syndromes & Myocardial Infarction Management 2.2 Heart Failure Syndromes & Cardiogenic Shock 2.3 Cardiac Arrhythmias, Conduction Blocks & BLS/ACLS Algorithms 2.4 Valvular Heart Disease, Infective Endocarditis & Hypertension

3 Chapter 3: Internal Medicine: Respiratory Medicine & Critical Care

3.1 Asthma & Chronic Obstructive Pulmonary Disease Exacerbations 3.2 Community-Acquired Pneumonia, Hospital-Acquired Pneumonia & Tuberculosis 3.3 Pulmonary Embolism, Pleural Effusion & Pneumothorax

4 Chapter 4: Internal Medicine: Endocrinology & Metabolic Disorders

4.1 Diabetes Mellitus, Diabetic Ketoacidosis & Hyperosmolar Hyperglycaemic State 4.2 Thyroid Disorders: Thyrotoxicosis, Hypothyroidism & Thyroid Storm 4.3 Adrenal Disorders, Pituitary Pathology & Calcium Homeostasis

5 Chapter 5: Internal Medicine: Gastroenterology, Hepatology & Nephrology

5.1 Upper & Lower Gastrointestinal Bleeding: Evaluation & Management 5.2 Cirrhosis, Portal Hypertension & Hepatic Encephalopathy 5.3 Acute Kidney Injury & Chronic Kidney Disease Staging 5.4 Fluid, Electrolyte & Acid-Base Emergencies

6 Chapter 6: Internal Medicine: Neurology, Haematology & Infectious Diseases

6.1 Stroke, Transient Ischaemic Attack & Acute Neurological Deficits 6.2 Sickle Cell Disease, Haemoglobinopathies & Transfusion Medicine 6.3 Dengue Fever, Arboviral Infections & Leptospirosis 6.4 HIV/AIDS, Opportunistic Infections & Antimicrobial Stewardship

7 Chapter 7: General Surgery: Acute Abdomen & Surgical Emergencies

7.1 Acute Abdomen: Peritonitis, Appendicitis & Acute Cholecystitis 7.2 Intestinal Obstruction, Bowel Ischaemia & Perforated Viscus 7.3 Abdominal Wall Hernias: Inguinal, Femoral, Umbilical & Strangulation 7.4 Upper & Lower GI Surgical Pathology & Postoperative Complications

8 Chapter 8: General Surgery: Trauma Resuscitation, Shock & Critical Care

8.1 ATLS Primary Survey & Hemorrhagic Shock Resuscitation 8.2 Thoracic Trauma: Tension Pneumothorax, Hemothorax & Flail Chest 8.3 Abdominal & Pelvic Trauma: FAST Examination & Damage Control Surgery 8.4 Traumatic Brain Injury, Burns & Wound Management

9 Chapter 9: General Surgery: Surgical Subspecialties & Perioperative Care

9.1 Urological Emergencies: Acute Retention, Renal Colic, Torsion & Hematuria 9.2 Musculoskeletal Trauma: Fractures, Dislocations & Compartment Syndrome 9.3 Preoperative Assessment, Surgical Site Infections & Fluid Management 9.4 Otolaryngology: Ear, Nose, Throat & Upper Airway Emergencies 9.5 Clinical Ophthalmology: Acute Red Eye, Glaucoma & Retinal Emergencies

10 Chapter 10: Obstetrics: Antenatal Care, Labor & Complications

10.1 Routine Antenatal Care, Screening & Fetal Assessment 10.2 Hypertensive Disorders of Pregnancy: Pre-eclampsia & Eclampsia 10.3 Antepartum Haemorrhage: Placenta Praevia & Placental Abruption 10.4 Normal Labor, Labor Dystocia & Obstetric Analgesia

11 Chapter 11: Obstetrics & Gynaecology: Postpartum & Pathology

11.1 Postpartum Haemorrhage, Normal Puerperium Physiology & Postpartum Care 11.2 Ectopic Pregnancy, Miscarriage & Gestational Trophoblastic Disease 11.3 Abnormal Uterine Bleeding & Pelvic Inflammatory Disease 11.4 Contraception, Cervical Cancer Screening & Gynaecological Malignancies 11.5 Obstetric & Gynaecological Instruments & Cervical Specimen Collection (PAP Smear Procedures)

12 Chapter 12: Paediatric Medicine: Neonatal Care, Growth & Nutrition

12.1 Neonatal Resuscitation, APGAR Scoring & Prematurity Complications 12.2 Neonatal Jaundice: Physiological, Pathological & Kernicterus 12.3 Growth Monitoring, Developmental Milestones & Failure to Thrive 12.4 Protein-Energy Malnutrition: Kwashiorkor, Marasmus & Nutritional Deficiencies

13 Chapter 13: Paediatric Medicine: Common Illnesses & Emergencies

13.1 Acute Gastroenteritis, Dehydration Assessment & WHO ORS Protocols 13.2 Paediatric Respiratory Illness: Croup, Bronchiolitis & Asthma 13.3 Childhood Infections, Exanthems & Caribbean Immunisation Schedules 13.4 Paediatric Surgical & Medical Emergencies: Intussusception & Febrile Seizures 13.5 Social Paediatrics, Child Protection & Vulnerable Child Health

14 Chapter 14: Psychiatry: Clinical Assessment & Psychopharmacology

14.1 Depressive Disorders, Bipolar Affective Disorder & Suicide Risk Assessment 14.2 Psychosis, Schizophrenia & Acute Delirium vs Dementia 14.3 Anxiety Disorders, Substance Misuse & Psychotropic Side Effects

15 Chapter 15: Community Health, Epidemiology & Preventive Medicine

15.1 Epidemiological Study Designs, Measures of Association & Bias 15.2 Screening Test Performance: Sensitivity, Specificity, PPV & NPV 15.3 Outbreak Investigation, Levels of Prevention & Caribbean NCD Control

16 Chapter 16: Internal Medicine: Rheumatology, Connective Tissue & Dermatology

16.1 Connective Tissue & Collagen Vascular Diseases 16.2 Bone & Joint Diseases: Non-Traumatic Arthropathies & Metabolic Bone Disorders 16.3 Clinical Dermatology: Common, Inflammatory, Bullous, Malignant & Drug-Induced Dermatoses

17 Chapter 17: Anaesthetics, Intensive Care & Clinical Measurements

17.1 Important Anaesthetic Techniques, Airway Management & Methods of Administration 17.2 Clinical Measurements & Intensive Care Monitoring: Cardiac Output, Arterial Blood Gases & Pulmonary Functions 17.3 Acute Pain Management, Multimodal Analgesia & Critical Care Sedation

3.2 Community-Acquired Pneumonia, Hospital-Acquired Pneumonia & Tuberculosis

Key Takeaways Explain This Topic AI

CURB-65 assigns one point each for new Confusion, Urea >7 mmol/L, Respiratory rate >=30/min, systolic BP <90 OR diastolic BP <=60 mmHg, and Age >=65. Combine the score with clinical judgement: 0–1 usually permits outpatient care, 2 warrants hospital assessment, and >=3 usually requires admission with critical-care review when appropriate.

Streptococcus pneumoniae is a leading bacterial cause of CAP; viruses commonly cause pneumonia in young children. Suspected atypical organisms (Mycoplasma pneumoniae, Legionella pneumophila) require empirical coverage with macrolides or respiratory fluoroquinolones.

Hospital-Acquired Pneumonia (HAP) develops >=48 hours after admission without incubation at admission. Choose empirical antibiotics using severity, prior cultures and local resistance data; add MRSA coverage when indicated by MRSA risk, local prevalence or severe illness.

Active pulmonary tuberculosis in the Caribbean requires prompt diagnosis via 3 morning sputum AFB smears, rapid molecular testing with GeneXpert MTB/RIF, and mycobacterial culture.

The standard first-line antitubercular regimen consists of 2 months of HRZE (Isoniazid, Rifampicin, Pyrazinamide, Ethambutol) followed by 4 months of HR (Isoniazid, Rifampicin), alongside routine Pyridoxine (vitamin B6) to prevent INH-induced peripheral neuropathy.

Last updated: November 2026

Lower Respiratory Infections in the Caribbean Context

Pneumonia and pulmonary tuberculosis remain prominent causes of acute morbidity, hospital admission, and mortality across the Caribbean basin. Clinical presentation is frequently modified by regional comorbidity burdens, notably poorly controlled diabetes mellitus, sickle cell disease, chronic kidney disease, and HIV infection. Clinicians practicing in regional hospitals must rapidly differentiate between typical and atypical pathogens, correctly assess disease severity to direct clinical triage, and maintain a high index of suspicion for Mycobacterium tuberculosis .

Community-Acquired Pneumonia (CAP)

Community-Acquired Pneumonia is an acute infection of the pulmonary parenchyma acquired outside of a healthcare facility. Clinically, it manifests with fever, productive cough, pleuritic chest pain, dyspnea, and signs of consolidation (dullness to percussion, bronchial breathing, and coarse inspiratory crackles).

Microbial Etiology

Streptococcus pneumoniae (Pneumococcus): A leading bacterial cause of CAP in adults and children; viruses commonly predominate in infants and preschool children. Classically presents with abrupt high fevers, rigors, pleuritic pain, and 'rusty' (prune juice) sputum. CXR demonstrates dense lobar consolidation with air bronchograms.

Haemophilus influenzae: Particularly prevalent among cigarette smokers, elderly patients, and those with underlying COPD or bronchiectasis.

Atypical Pathogens:

Mycoplasma pneumoniae: Most common in young adults and school-age children. Presents with insidious onset, dry hacking cough, low-grade fever, headache, and prominent extrapulmonary features, including autoimmune hemolytic anemia (cold agglutinins), erythema multiforme, and bullous myringitis.

Legionella pneumophila: Transmitted via inhalation of aerosolized water from contaminated air-conditioning cooling towers, hotel water systems, or hospital plumbing. Characterized by severe multisystem disease: high remittent fever, relative bradycardia (Faget's sign), confusion/encephalopathy, watery diarrhea, hyponatremia (due to SIADH and renal wasting), and elevated hepatic transaminases. Diagnosed via urinary antigen testing.

Chlamydophila pneumoniae: Insidious pharyngitis and hoarseness followed by prolonged bronchitis.

Staphylococcus aureus: Often causes severe necrotizing pneumonia with cavitation and pneumatoceles following an antecedent influenza viral infection. Associated with high mortality.

Klebsiella pneumoniae: Classically affects chronic alcohol misusers, malnourished individuals, and diabetics. Produces cavitating upper lobe consolidation with characteristic thick 'currant-jelly' sputum.

Severity Stratification: The CURB-65 Score

CURB-65 estimates adult CAP mortality risk. Combine it with clinical judgement, oxygenation, organ-support needs and comorbidities when deciding the site of care; the score alone does not determine ICU admission.

Criteria (1 Point for Each Present):

C — Confusion: New mental confusion defined as an Abbreviated Mental Test Score (AMTS) <= 8, or new disorientation in person, place, or time.

U — Urea: Serum urea > 7.0 mmol/L (Blood Urea Nitrogen BUN > 19 mg/dL).

R — Respiratory Rate: Respiratory rate >= 30 breaths/min.

B — Blood Pressure: Systolic BP < 90 mmHg OR Diastolic BP <= 60 mmHg.

65 — Age: Age >= 65 years.

(Note: In outpatient primary care clinics where laboratory urea is not immediately accessible, the CRB-65 score is utilized. A score of 0 indicates low risk, 1-2 warrants hospital assessment, and 3-4 requires urgent hospital admission).

CURB-65 Triage & Mortality Risk Table

  • CURB-65 Score 30-Day Mortality Risk Category Clinical Management Setting
  • 0 - 1 < 3% Low Risk Outpatient care suitable; oral antibiotic therapy; primary care follow-up
  • 2 ~9% Intermediate Risk Inpatient admission to general medical ward; oral or IV therapy
  • 3 ~15% - 20% High Risk Urgent hospital admission ; IV dual therapy; assess for ICU / HDU

4 - 5 > 30% - 40% Severe / Critical Urgent admission and critical-care assessment ; resuscitation and IV therapy; ICU admission according to organ-support needs

Empirical Antimicrobial Regimens for CAP

Antimicrobial selection must balance coverage for typical pyogenic bacteria with atypical pathogens.

Outpatient CAP (CURB-65 0-1):

First-line: Oral Amoxicillin 500 mg to 1 g TDS for 5 days.

Penicillin-allergic or suspected atypical pathogen: Oral Doxycycline 100 mg BD or oral Clarithromycin 500 mg BD (or Azithromycin 500 mg OD).

Inpatient Non-Severe CAP (CURB-65 2):

Dual therapy: IV Co-amoxiclav 1.2 g TDS or oral Co-amoxiclav 500/125 mg TDS (or IV Ceftriaxone 1 g to 2 g OD ) PLUS oral Clarithromycin 500 mg BD (or Azithromycin 500 mg OD).

Alternative monotherapy: Respiratory fluoroquinolone (Levofloxacin 500 mg OD or Moxifloxacin 400 mg OD).

Severe Inpatient CAP / ICU (CURB-65 >= 3):

Immediate intravenous dual therapy: IV Ceftriaxone 2 g OD (or IV Co-amoxiclav 1.2 g TDS) PLUS IV Clarithromycin 500 mg BD .

If Pseudomonas is suspected (structural lung disease, bronchiectasis): IV Piperacillin-tazobactam 4.5 g 6-8 hourly plus IV Ciprofloxacin 400 mg 12-hourly.

Hospital-Acquired Pneumonia (HAP) & Ventilator-Associated Pneumonia (VAP)

Definition: Pneumonia developing >= 48 hours after hospital admission that was not incubating at the time of admission. Ventilator-Associated Pneumonia (VAP) arises >= 48 hours following endotracheal intubation.

Microbiology: Shifts away from community pathogens toward multidrug-resistant hospital microflora:

Gram-negative bacilli: Pseudomonas aeruginosa , Klebsiella pneumoniae , Enterobacter , Escherichia coli , Acinetobacter baumannii .

Gram-positive cocci: Methicillin-Resistant Staphylococcus aureus (MRSA).

Empirical Therapy:

Monotherapy for low MDR risk: IV Piperacillin-tazobactam 4.5 g 6-8 hourly, or IV Ceftazidime 2 g 8-hourly, or IV Meropenem 1 g 8-hourly.

MRSA risk or suspicion (guided by prior antibiotics/cultures, local prevalence and mortality risk): Add IV Vancomycin (initially 15–20 mg/kg every 8–12 hours in adults with normal renal function, then adjust to renal function and AUC24 400–600 mg·h/L, assuming MIC 1 mg/L) or IV Linezolid (600 mg 12-hourly).

Tuberculosis (TB) in the Caribbean

Tuberculosis remains a major public health priority across the Caribbean archipelago. Co-infection with HIV represents the single greatest risk factor for active disease, accelerating progression from latent infection to active, contagious tuberculosis.

Transmission and Pathogenesis

Transmitted via airborne droplet nuclei (1-5 um) aerosolized during coughing or speaking by individuals with active cavitary pulmonary TB.

Primary TB: Inhaled bacilli implant in the subpleural mid-to-lower lung fields, forming an inflammatory lesion ( Ghon focus ). Spread to draining hilar lymph nodes creates the classic Ghon complex . Over time, this lesion fibroses and calcifies into a Ranke complex . In immunocompetent hosts, cell-mediated immunity contains the infection within caseating granulomas (latent TB).

Post-Primary (Reactivation) TB: Occurs when host cell-mediated immunity wanes (HIV, malnutrition, diabetes, chronic steroid use, aging). Typically localizes to the apical and posterior segments of the upper lobes due to higher ventilation-perfusion ratios and high alveolar oxygen tension (PaO2). Characterized by extensive caseous necrosis, liquefaction, cavitation, and erosion into airways.

  • Clinical Presentation
  • Chronic productive cough persisting for > 2 to 3 weeks
  • Hemoptysis (ranging from blood-streaked sputum to massive hemorrhage from eroded Rasmussen's aneurysms)
  • Drenching night sweats, low-grade fevers, anorexia, and progressive unintentional weight loss ('consumption')
  • Cachexia, pallor, and apical crackles on physical examination
  • Diagnostic Workup

Sputum Examination: Collect three early-morning sputum specimens for Acid-Fast Bacilli (AFB) smear microscopy using Ziehl-Neelsen (ZN) or fluorochrome (auramine-rhodamine) staining.

GeneXpert MTB/RIF Assay: The World Health Organization (WHO) recommended frontline diagnostic test. This automated, cartridge-based nucleic acid amplification test (NAAT) detects Mycobacterium tuberculosis DNA and simultaneously identifies mutations in the rpoB gene conferring rifampicin resistance within 2 hours.

Mycobacterial Culture: Liquid media (BACTEC MGIT) and solid media (Löwenstein-Jensen). Remains the gold standard for definitive diagnosis and comprehensive phenotypic drug susceptibility testing (DST).

Chest Radiography: Demonstrates apical patchy infiltrates, thick-walled cavitary lesions with air-fluid levels, pleural effusions, or diffuse 1-2 mm uniform 'millet-seed' nodules in miliary tuberculosis.

First-Line Antitubercular Therapy (The RIPE Regimen)

Standard therapy for drug-susceptible pulmonary tuberculosis consists of a 6-month regimen divided into two phases:

Intensive Phase (2 Months): Rifampicin, Isoniazid, Pyrazinamide, Ethambutol ( 2HRZE ).

Continuation Phase (4 Months): Rifampicin and Isoniazid ( 4HR ).

Medication Profiles, Toxicities & Clinical Monitoring

Drug Mechanism of Action Major Adverse Effects Clinical Pearls & Monitoring

Rifampicin (R) Inhibits bacterial DNA-dependent RNA polymerase Potent hepatic CYP450 inducer; hepatotoxicity; thrombocytopenia Harmless orange/red discoloration of urine, sweat, saliva, and tears (warn patients); dramatically reduces levels of oral contraceptives, warfarin, and protease inhibitors

Isoniazid (H) Inhibits mycolic acid cell wall synthesis Peripheral neuropathy (pyridoxine antagonism); hepatotoxicity; drug-induced lupus Must co-prescribe Pyridoxine (vitamin B6) 10-25 mg daily to prevent neuropathy. Discontinue if transaminases > 5x ULN (asymptomatic) or > 3x ULN with symptoms

Pyrazinamide (Z) Discharges membrane potential in acidic phagosomes Hyperuricemia (inhibits renal urate excretion); severe hepatotoxicity; polyarthralgias Can precipitate acute gouty arthritis. The most hepatotoxic drug in the standard first-line regimen

Ethambutol (E) Inhibits arabinosyl transferase (cell wall synthesis) Retrobulbar optic neuritis (decreased visual acuity, red-green color blindness) Test baseline visual acuity (Snellen chart) and color vision (Ishihara plates). Stop immediately if visual changes occur. May be used in young children when indicated at recommended weight-based doses, with age-appropriate monitoring

Loading diagram... Pneumonia Severity Triage & Tuberculosis Diagnostic Pathway